X4 Pharmaceuticals, Inc. (XFOR)
| Market Cap | 318.59M -5.8% |
| Revenue (ttm) | 16.96M -50.1% |
| Net Income | -80.52M |
| EPS | -0.66 |
| Shares Out | 102.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 501,341 |
| Open | 3.200 |
| Previous Close | 3.170 |
| Day's Range | 2.975 - 3.200 |
| 52-Week Range | 2.430 - 4.830 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 11.60 (+271.8%) |
| Earnings Date | Nov 4, 2026 |
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta... [Read more]
Financial Performance
In 2025, X4 Pharmaceuticals's revenue was $35.11 million, an increase of 1273.21% compared to the previous year's $2.56 million. Losses were -$79.20 million, 111.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price target is $11.6, which is an increase of 271.80% from the latest price.
News
X4 Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
The 4WARD trial targets enrollment completion by year-end 2026 and topline data in Q1 2028, following a sample-size reduction and improved enrollment operations. Management outlined a 15,000-30,000-patient opportunity, a G-CSF tapering study, and funding into 2029.
X4 Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
The pivotal 4WARD trial remained on track to finish enrollment by year-end 2026, with top-line results expected by the end of Q1 2028. Management sees a 15,000–30,000-patient opportunity and said $188M in cash supports commercialization.
X4 Pharmaceuticals reports Q3 EPS (16c), consensus (19c)
Reports Q3 revenue $2.88M, consensus $2.3M. “With topline data from both our global 4WARD trial and our new 4STEPS trial expected in the first quarter of 2028, we believe mavorixafor…
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 -
X4 Pharmaceuticals Quarterly report: Q3 2026
X4 Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 4, 2026.
X4 Pharmaceuticals Earnings release: Q3 2026
X4 Pharmaceuticals released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will part...
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -
X4 Pharmaceuticals Transcript: Investor Day 2026
4WARD enrollment is expected to finish in Q4 2026, with top-line data in Q1 2028; positive results could support approval in late 2028 or early 2029. Market research points to a 15,000-patient initial PCN opportunity, potentially extending to 30,000, and cash runway into 2029.
X4 Pharmaceuticals Slides: FY 2026
X4 Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 29, 2026.
X4 Pharmaceuticals Press release: FY 2026
X4 Pharmaceuticals issued a press release on October 29, 2026, disclosing material business information to investors.
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, Octo...
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
- Repayment of Existing Loan Facility Completed - - Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WAR...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on Septem...
X4 Pharmaceuticals Slides: Corporate presentation
X4 Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
X4 Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Mavorixafor's phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. Operational changes have improved enrollment, and a new study will address G-CSF reduction. Commercial launch is targeted for late 2028 or early 2029.
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will par...
X4 Pharmaceuticals announces results from Type C Meeting with FDA
X4 Pharmaceuticals (XFOR) announced the outcome of its Type C Meeting with the FDA related to the global 4WARD Phase 3 clinical trial. The purpose of the meeting was to…
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GL...
X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation
X4 Pharmaceuticals (XFOR)’ mavorixafor was granted FDA orphan designation as a treatment of congenital neutropenia, according to a post to the agency’s website.
X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)
Reports Q2 revenue $8.81M, consensus $2.42M. “Since we began leading X4 last August, we have taken meaningful actions to strengthen the execution of the mavorixafor Phase 3 4WARD trial in…
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the ...
X4 Pharmaceuticals Quarterly report: Q2 2026
X4 Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
X4 Pharmaceuticals Earnings release: Q2 2026
X4 Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
X4 Pharmaceuticals initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of X4 Pharmaceuticals (XFOR) with an Overweight rating and $11 price target The firm believes the Street is materially underestimating the probability of Phase 3 success...